Posted by Michael Wonder on 29 Oct 2023
Coherus and Junshi Biosciences announce FDA pproval of Loqtorzi (toripalimab-tpzi) in all lines of treatment for recurrent or metastatic nasopharyngeal carcinoma
27 October 2023 - Loqtorzi is the first and only FDA approved treatment for nasopharyngeal carcinoma.
Coherus BioSciences and Shanghai Junshi Biosciences today announced that the US FDA approved Loqtorzi (toripalimab-tpzi) in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma, and as monotherapy for the treatment of adults with recurrent, unresectable, or metastatic nasopharyngeal carcinoma with disease progression on or after platinum-containing chemotherapy.
